Ozempic maker's shares plunge after failed weight-loss trial [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Shares in Novo Nordisk have fallen by more than a quarter after the Ozempic maker revealed a set of underwhelming results in a trial for its next-generation obesity drug. A drop of 29pc led to as much as 736bn Danish krone (£82bn) being wiped off the company's valuation on Friday, which is equivalent to nearly a quarter of Denmark's GDP. Investors took fright after a late-stage trial for Novo's CagriSema showed lower-than-expected weight loss, dealing a blow to the Danish company's attempts to release a more effective successor to its Wegovy weight-loss jab. The CagriSema trial showed the drug helped patients cut their overall weight by 22.7pc, which was below the 25pc that Novo Nordisk had expected. The effectiveness is similar to the 23pc reported for Zepbound, which is already on sale by rival Eli Lilly. Simon Baker, a pharmaceuticals analyst at Redburn Atlantic, said: “They sought a superior result to Lilly and got one that is the same.” The results are a “worst-case sc
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- FDA approves Alhemo® injection as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B with inhibitors [Yahoo! Finance]Yahoo! Finance
- Eli Lilly's obesity drug Zepbound gains approval to treat sleep apnea [USA TODAY]USA TODAY
- Why Viking Therapeutics Tumbled by More Than 10% This Week [Yahoo! Finance]Yahoo! Finance
- Stock market today: Dow, S&P 500, Nasdaq rebound on fresh inflation data to cap volatile week [Yahoo! Finance Canada]Yahoo! Finance Canada
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/7/24 - Beat
NVO
Sec Filings
- 12/20/24 - Form 6-K
- 12/20/24 - Form 6-K
- 12/18/24 - Form 6-K
- NVO's page on the SEC website